Drug Profile
Research programme: peptide therapeutics - XImmune
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator XImmune
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Adult respiratory distress syndrome; Septic shock
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Septic shock
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Septic shock in Sweden (unspecified route)
- 06 Sep 2023 Discontinued for Adult respiratory distress syndrome in Sweden (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Septic-shock in Sweden